reworking sweet into purchaser insights via long-term partnerships

Transforming candy into customer insights through long-term partnerships | #SAPPHIRENOW

Hershey is a logo that we can all embody, but chocolate and theme parks are simplest a part of thecommercial enterprise. So while the company’s CEO articulates in public that he considers Hershey to be aknowledge and perception organisation — that just happens to make chocolate — it is vital to pick outthe right companions to realise that vision.
Carlos Amesquita, CIO on the Hershey Co.; Henrik Wagner, worldwide SAP Alliance Lead at Virtustream, Inc.; and Clay Caldwell, national vice president, Americas, HANA enterprise Cloud at SAP SE, met with Peter Burris (@plburris), cohost of theCUBE, from the SiliconANGLE Media team, throughout the recent SAP Sapphire 2016 occasion to speak about Hershey’s technological transformation.
transforming a organisation

Amesquita advised theCUBE that Hershey is a customer-centric, consumertargeted, branded employerthat depends on deep insights about what the consumers need, what they want and the way to get it to them on the time they want it.
that during itself is a tall order for any IT enterprise,” he said. but, whilst he joined the agency with a mandate to create a main analytics business enterprise, he defined that a change to the business enterprise’s complete platform of structures for velocity and for handing over those insights becomevital.
Transformation partners

Burris remarked to Amesquita that Hershey has a history of right client and employee engagement. Why did you pick to work with SAP and Virtustream?” he requested?
Noting the good sized era shift blended with cloud and analytics, Amesquita remarked,” at some point youwant to change from were you’re and wherein you need to be.” He carefully picked who could lead theexchange and established a completely sturdy partnership with the management of each SAP and Hershey. “So it’s not only about a contract or implementation; it’s miles about a strategic lengthytime period partnership,” he delivered.
Virtustream comes into the picture as a systems integrator, and the corporation is a key component tohelping Hershey obtain its plans. Amesquita chose Virtustream because he believes in virtualization inside the longterm and feels it’s miles a need to electricity the agency’s transformation.
associated: fb’s position in getting groups to open up their era | #OCPSummit16
persevering with the transformation

Wagner advised Burris how Virtustream is happy to be operating with SAP and around S/4HANA Cloud topower innovation for Hershey. “we’ve a really large consciousness going into the project … coming from our management down,” he said. “Being there in the beginning of the mission, as we’re kicking it off now,all of the way thru the adventure, we sense humbled to be a part of it.”
Caldwell talked about that the Hershey, SAP, Virtustream partnership has been ongoing for the past six months. “With Hershey dipping their large toe inside the water with a assignmentessential agencysoftware and commercial enterprise warehouse setting that during our HANA company Cloud with Virtustream … they may be now shifting forward the totality in their surroundings onto HANA companyCloud,” he said.
Watch the full interview underneath, and be sure to check out more of SiliconANGLE and theCUBE’scoverage of SAP Sapphire 2016.

E-cigarette use in Britain holds steady

Smoking records for international No Tobacco Day
statistics from Kantar Media TGI shows the number of British people smoking e-cigarettes is holdingregular at 6.ninety three%. This compares to the 2014 figure of 6.seventy seven% and remainsconsiderably higher than France (2.89%), Germany (2.forty seven%) and Spain (2.66%).

In August 2015, Public fitness England posted a assessment approximately e-cigarettes, announcing that e-cigarettes are ninety five% safer than cigarettes and are an powerful quitting aid. it’s miles predictedthat e-cigarettes may be regulated as scientific products in 2016, so they can be made available by the NHS on prescription.

when we examine e-cigarette utilization with ordinary cigarette utilization, it nonetheless a ways much less popular. the proportion of people who say they smoke regular cigarettes in the uk stands atsixteen.five%, down from 17.4% in 2014, 21.1% in 2013 and 22.three% in 2011.

each year, the arena fitness business enterprise (WHO) marks world No Tobacco Day (WNTD), to “highlight the fitness risks associated with tobacco use and advise for effective guidelines to lessentobacco consumption.” This year the day is on the 31st may additionally 2016, and who is calling onnations to get ready for simple packaging of tobacco merchandise. study more at the WHO website.

supply : Kantar health

Chemo for person Sarcomas: Murky facts and specialists’ Insights

If there’s one issue that every one sarcoma experts can agree on, it’s the fact that no two sarcomaprofessionals appear to completely agree on the relative benefits and dangers of the usage ofneoadjuvant or adjuvant chemotherapy in adults with gentle-tissue sarcomas.

The confusion is partly due to this tough fact: 86f68e4d402306ad3cd330d005134dac, authoritative recordsare hard to return through in sarcoma.

“There had been as a minimum 22 randomized scientific trials looking to see if neoadjuvant or adjuvant chemotherapy has any impact on remedy fees in patients with resectable sarcomas, and notwithstanding22 research, the jury remains out,” said Edwin Choy, MD, PhD, a medical oncologist on the middle for Sarcoma and Connective Tissue Oncology at the Massachusetts trendy hospital cancer center in Boston.

“So 4 or 5 of these research are advantageous, which means they sayyes, we ought to do it”, 4 or 5studies are bad, which means that people who were given the chemotherapy honestly did worse — had a decrease therapy fee than folks that didn’t get any chemotherapy — after which the opposite 12 or sostudies are largely inconclusive,” he stated in an interview with Medscape medical information.

Lee J. Helman, MD, head of the molecular oncology segment of the pediatric oncology branch on thenational cancer Institute’s center for most cancers studies in Bethesda, Maryland, agreed, noting that when investigators try to solution this query by carrying out systematic opinions and meta-analyses, “you get 3 research which might be positive, and 3 studies which can be terrible.”

big medical trials with doubtlessly authoritative results are hard to behavior due to sarcomas’ rarity,which means that that research are typically small and underpowered, Dr Choy stated.

Dr Helman, but, is quick to factor out that for pediatric patients with the extra not unusual sarcomas — Ewing sarcoma, osteosarcoma, and rhabdomyosarcoma — the benefits of neoadjuvant chemotherapy are unequivocal.

“The consensus is that [these] pediatric sarcomas sincerely advantage from neoadjuvant chemotherapy, andalmost all sufferers get neoadjuvant chemotherapy,” he stated in an interview with Medscape clinical news.

nonetheless, some pediatric sarcomas are like grownup sarcomas.

whilst you get to pediatric sarcomas which can be greater like adult smooth tissue sarcomas, but, theytend to be less chemosensitive. The problem is that many, many studies test a drug in [adult] ‘soft-tissue sarcomas,’ and soft-tissue sarcomas are many, many histologies,” he said.

research of two drugs recently accredited by using the us food and Drug administration to be used in adults with sarcoma — trabectedin (Yondelis, Janssen Oncology) and pazopanib (Votrient, Novartis) — excluded sufferers with positive sarcomas that have been not going to be attentive to the medicine,however nevertheless included patients with some of exceptional sarcoma histologies to have enoughpatients to hit upon a treatment distinction, Dr Helman mentioned.

For maximum sarcomas, the great remedy is complete resection with adequate surgical margins. wherethere seems to be consensus that chemotherapy may be useful is in sufferers with tumors larger than fivecm, deeply seated tumors, and people with high-grade histology, he said. hold reading
further to surgical treatment and radiation, Dr Choy and colleagues tend to choose multidrug neoadjuvant chemotherapy and radiation for highhazard sarcomas with histologies which are touchy to chemotherapy,inclusive of synovial sarcoma and myxoid liposarcoma.

In assessment, myxofibrosarcomas and chondrosarcomas have a tendency to be insensitive to chemotherapy, and patients with those types of sarcoma would be not likely to gain. The selection is also based totally at the presence of excessivethreat capabilities, together with tumor size, intensity, grade, and affected person age.

In general, Dr Helman recommends chemotherapy for younger, healthier sufferers who’re able towithstand the rigors of cytotoxic chemotherapy and feature highrisk tumors.

In his discussion of the relative risks and benefits, he tells grownup patients that the informationassisting the recommendation are “now not compelling” due to the lack of randomized trial facts.

Dr Helman could also say, when fitting, that “I consider that these tumors are probable to be touchy to chemotherapy, and i trust our first-class shot is to deal with it at our first cross spherical.”

puppy concept

despite the fact that the proof is spotty, there are records that seem to aid the use of neoadjuvant chemotherapy in person sarcomas.

As pronounced through Medscape clinical news, a observe published in 2005 and a current meta-analysis showed that during patients with tender-tissue sarcomas of the extremities, 18F-fluorodeoxyglucose positron emission tomography (18F-FDG-pet) should provide useful prognostic factsbased totally on most standardized uptake values (SUVmax) of 18F-FDG.

within the 2005 observe, each SUVmax before neoadjuvant chemotherapy and alternate in SUVmax after chemotherapy independently recognized patients at excessive hazard for tumor recurrence.

A coauthor of that take a look at, Janet F. Eary, MD, professor of radiology and director of the advancedImaging Facility at the university of Alabama college of medicine in Birmingham, told Medscape scientificinformation that “while we validated that records, what it confirmed turned into that inside thepopulation we taken care of, chemotherapy — neoadjuvant chemotherapy — really had an effect.”

Dr Eary stated that she and her colleagues have supported the benefits of neoadjuvant chemotherapy ingentle-tissue sarcomas for the reason that past due Nineties, and that “we’ve by no means understood” why it isn’t used extra consistently in either the usa or Canada.

The trouble With examine statistics on an extraordinary most cancers

The specialists interviewed via Medscape medical information similarly defined how and why theinformation on chemotherapy and sarcomas are murky.

soft-tissue sarcomas account for much less than 1% of all cancers recognized inside the u.s., with anenvisioned 12,000 new cases annually. The relative rarity of sarcomas makes it hard for investigators to recruit sufficient sufferers for effectively powered scientific trials, and as a result, for each look atsuggesting a gain for chemotherapy, there is an same and opposite study showing equivocal gain atexcellent.

whilst it is commonplace to do adjuvant or neoadjuvant chemotherapy research in 2000 patients with lungmost cancers, for example, “you may believe how difficult it’ll be to do a 2000-affected person study in sarcoma. And so, in case you best do a three hundredaffected person study, then that examine wouldsimplest be positive if statistically the dimensions of the impact became large,” Dr Choy defined.

The efficacy of chemotherapy in sarcoma in general might be extraordinarily modest, he stated.

it is not the case that everybody who doesn’t get chemotherapy will die in their sickness quickly, andeach person who gets chemotherapy can be cured for all time. If that were the case, then we ought tolocate it out with a tenpatient observe,” he stated.

some other problem with medical trials is that to accrue enough patients for properly powered research, investigators have often lumped together sarcomas with distinct histologies with differing tiers of responsiveness to chemotherapy, Dr Choy said, echoing Dr Helman’s feedback.

Edwin Choy is the reporter’s clinical oncologist. Dr Choy, Dr Helman, and Dr Eary reported no applicablefinancial relationships.

worldwide meat market insights

Kiwi chef Al Brown (left) at the Alliance conference with Queenstown farmers Lucy and James Clouston, who manage Walter Peak Station. Louise Scott.

Kiwi chef Al Brown (left) at the Alliance conference with Queenstown farmers Lucy and James Clouston, whocontrol Walter peak Station. Louise Scott.
Farmers from throughout New Zealand had been in Queenstown this week for the Alliance natural Southconvention.

various national and international audio system addressed the one hundred eightysturdy target audience to speak about international market tendencies, consumer insights and ways to improve farmproductiveness and profitability.

The Invercargill-based Alliance institution is owned by means of about 5000 farmer shareholders and isthe arena‘s largest processor and exporter of sheep meat.

visitor speakers on the Queenstown conference blanketed Simon Peterson, chief executive Rowing New Zealand, Stephen Bradley, from Queenstown’s famous burger bar Fergburger, Tony Ruffo, president of The Lamb organization North the united states and Kiwi chef and writer Al Brown.

Mr Brown grew up on a farm, however instructed the target market he in no way wanted to be a farmer,an awful lot to the frustration of his father.

He become eager on the hunter-gatherer side of things and this sparked his love of meals.

His restaurants consciousness on “casual mealsworking in particular with secondary cuts of meat.

He sells skirt steak in his eating place, includes offal in his recipes and says pork hocks can hold a hugeamount of flavour.

Tony Ruffo, president of The Lamb organization, flew in from the usa to wait the convention. His agencyimports 38,000 tonnes of new Zealand lamb annually.

He defined the Kiwi product as “exceptional in class.”

The convention finished the day before today.